pAKT pathway activation is associated with


Journal

NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891

Informations de publication

Date de publication:
2019
Historique:
received: 27 05 2018
accepted: 08 01 2019
entrez: 8 2 2019
pubmed: 8 2 2019
medline: 8 2 2019
Statut: epublish

Résumé

Numerous studies have focused on the PI3K/AKT/mTOR pathway in estrogen receptor positive (ER) breast cancer (BC), as a linear signal transduction pathway and reported its association with worse clinical outcomes. We developed gene signatures that reflect the level of expression of phosphorylated-Serine473-AKT (pAKT) and phosphorylated-Serine2448-mTOR (p-mTOR) separately, capturing their corresponding level of pathway activation. Our analysis revealed that the pAKT pathway activation was associated with luminal A BC while the p-mTOR pathway activation was more associated with luminal B BC (Kruskal-Wallis test

Identifiants

pubmed: 30729154
doi: 10.1038/s41523-019-0102-1
pii: 102
pmc: PMC6355773
doi:

Types de publication

Journal Article

Langues

eng

Pagination

7

Déclaration de conflit d'intérêts

The authors declare no competing interests.

Références

Biochem J. 1999 Dec 1;344 Pt 2:427-31
pubmed: 10567225
Cancer Res. 2000 Jul 1;60(13):3504-13
pubmed: 10910062
Nature. 2002 Jan 31;415(6871):530-6
pubmed: 11823860
Nucleic Acids Res. 2002 Apr 1;30(7):1575-84
pubmed: 11917018
N Engl J Med. 2002 Dec 19;347(25):1999-2009
pubmed: 12490681
Lancet. 2003 May 10;361(9369):1590-6
pubmed: 12747878
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
pubmed: 12829800
Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8
pubmed: 12917485
Cancer Res. 2003 Nov 1;63(21):7167-75
pubmed: 14612510
Science. 2004 Apr 23;304(5670):554
pubmed: 15016963
Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13489-94
pubmed: 15342917
Cancer Res. 2004 Nov 1;64(21):7678-81
pubmed: 15520168
Lancet. 2005 Feb 19-25;365(9460):671-9
pubmed: 15721472
Cell. 2005 Apr 22;121(2):179-93
pubmed: 15851026
Oncogene. 2005 Jul 7;24(29):4660-71
pubmed: 15897907
J Biol Chem. 2005 Jul 8;280(27):25485-90
pubmed: 15899889
Nature. 2005 Jul 28;436(7050):518-24
pubmed: 16049480
Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13550-5
pubmed: 16141321
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nature. 2006 Jan 19;439(7074):353-7
pubmed: 16273092
Breast Cancer Res. 2005;7(6):R953-64
pubmed: 16280042
Nat Rev Drug Discov. 2005 Dec;4(12):988-1004
pubmed: 16341064
Cancer Cell. 2006 Feb;9(2):121-32
pubmed: 16473279
J Natl Cancer Inst. 2006 Feb 15;98(4):262-72
pubmed: 16478745
Nature. 2006 May 25;441(7092):523-7
pubmed: 16680151
J Clin Oncol. 2006 Sep 10;24(26):4236-44
pubmed: 16896004
Nature. 2006 Aug 17;442(7104):779-85
pubmed: 16915281
Cancer Cell. 2006 Dec;10(6):529-41
pubmed: 17157792
J Clin Oncol. 2007 Apr 1;25(10):1239-46
pubmed: 17401012
Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6740-5
pubmed: 17420468
BMC Cancer. 2007 Apr 11;7:61
pubmed: 17428335
Proc Natl Acad Sci U S A. 2007 May 1;104(18):7564-9
pubmed: 17452630
Clin Cancer Res. 2007 Jun 1;13(11):3207-14
pubmed: 17545524
Cell. 2007 Jun 29;129(7):1261-74
pubmed: 17604717
Cancer Cell. 2007 Jul;12(1):9-22
pubmed: 17613433
Breast Cancer Res Treat. 2008 Jun;109(3):491-501
pubmed: 17659439
Lancet Oncol. 2007 Dec;8(12):1071-1078
pubmed: 18024211
J Clin Oncol. 2008 Mar 10;26(8):1275-81
pubmed: 18250347
Breast Cancer Res Treat. 2008 Mar;108(2):191-201
pubmed: 18297396
Breast Cancer Res. 2008;10(2):R34
pubmed: 18430221
BMC Genomics. 2008 May 22;9:239
pubmed: 18498629
Breast Cancer Res Treat. 2009 Jul;116(1):69-77
pubmed: 18592372
Cancer Res. 2008 Jul 1;68(13):5405-13
pubmed: 18593943
PLoS Genet. 2008 Jul 18;4(7):e1000129
pubmed: 18636107
Breast Cancer Res Treat. 2009 Jul;116(2):303-9
pubmed: 18821012
Nature. 2009 Jun 18;459(7249):1005-9
pubmed: 19421193
Clin Cancer Res. 2009 Aug 15;15(16):5049-59
pubmed: 19671852
Breast Cancer Res Treat. 2010 Jun;121(3):575-89
pubmed: 19688261
Breast Cancer Res Treat. 2010 Oct;123(3):661-77
pubmed: 19960244
Breast Cancer Res. 2010;12(1):R5
pubmed: 20064235
J Clin Oncol. 2010 Mar 1;28(7):1145-53
pubmed: 20100965
Breast Cancer Res. 2010;12(2):R21
pubmed: 20346151
Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10208-13
pubmed: 20479250
Breast Cancer Res Treat. 2010 Jul;122(2):419-28
pubmed: 20480226
J Clin Oncol. 2010 Sep 20;28(27):4111-9
pubmed: 20697068
Breast Cancer Res. 2010;12(5):R68
pubmed: 20813035
PLoS One. 2010 Dec 01;5(12):e15031
pubmed: 21152022
EMBO Mol Med. 2011 Dec;3(12):726-41
pubmed: 21910250
N Engl J Med. 2012 Feb 9;366(6):520-9
pubmed: 22149876
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Mol Cancer Ther. 2014 May;13(5):1021-31
pubmed: 24748656
Cancer Treat Rev. 2016 Apr;45:87-96
pubmed: 26995633
Cancer Cell. 2016 Aug 8;30(2):229-242
pubmed: 27451907
Int J Oncol. 2018 Feb;52(2):424-432
pubmed: 29207087
J Biol Chem. 1997 Nov 21;272(47):29911-8
pubmed: 9368067

Auteurs

Amir Sonnenblick (A)

1Oncology Division, Tel Aviv Sourasky Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

David Venet (D)

2Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

Sylvain Brohée (S)

2Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

Noam Pondé (N)

2Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

Christos Sotiriou (C)

2Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

Classifications MeSH